Freenome

FreenomeFreenome
Freenome

Freenome

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

DR 56Speed 542014Active402South San Francisco, USA
Rate

About

Freenome is a biotechnology company dedicated to outpacing cancer through early detection. Their intelligent screening platform utilizes multiomics technology and artificial intelligence, combined with a standard blood draw, to identify cancer in its earliest, most treatable stages. This approach aims to make a significant difference by enabling earlier intervention and improving patient outcomes.
Frequently asked

What does Freenome do?

Freenome is a biotechnology company dedicated to outpacing cancer through early detection. Their intelligent screening platform utilizes multiomics technology and artificial intelligence, combined with a standard blood draw, to identify cancer in its earliest, most treatable stages. This approach aims to make a significant difference by enabling earlier intervention and improving patient outcomes.

What is Freenome's revenue?

StartupHub estimates Freenome's annual revenue at $41.7M (range $22.3M to $135.5M, 68% confidence), based on comparable companies in the sector.

What is Freenome's valuation?

StartupHub estimates Freenome's effective valuation at $563.3M (range $394.3M to $732.2M, 27% confidence), based on comparable companies in the sector.

How much funding has Freenome raised?

Freenome has raised a total of $570M in funding. The most recent round on record is Series D.

Where is Freenome headquartered?

Freenome is headquartered in South San Francisco, California, USA.

When was Freenome founded?

Freenome was founded in 2014.

What industry does Freenome operate in?

Freenome operates in Biotechnology, Healthcare, Artificial Intelligence, Biotech, MedTech, HealthTech.

How many employees does Freenome have?

Freenome has approximately 402 people on record.

HEADCOUNT
402
DOMAIN RATING
56
Comments

No comments yet. Be the first to share your take.